Detailseite
Projekt Druckansicht

Untersuchungen zum Einfluss der Glykosylierung des Sars-CoV-2 Hüllproteins auf die Humanpathogenität des Virus

Antragsteller Dr. Thomas Rexer
Fachliche Zuordnung Virologie
Förderung Förderung von 2021 bis 2022
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 458633485
 
Erstellungsjahr 2022

Zusammenfassung der Projektergebnisse

It is estimated that infections with the SARS-CoV-2 virus have caused around 6 Mio fatalities worldwide as of April 2022. SARS-CoV-2 exhibits a protein envelope. The spike protein is the dominant protein of the viral envelope and responsible for virus entry into host cells. Moreover, the spike protein is heavily glycosylated and while multiple functions are associated with glycans on the surfaces of viruses, the impact of specific glycoforms on the immunogenicity is poorly characterized. The main reason is that robust processes for generating homogenous glycoforms are missing. Through the DFG-funded project “Deciphering the impact of SARS- CoV-2 envelope protein glycosylation on human pathogenicity”, we have successfully established a platform for tailoring the glycosylation of insect cell-derived SARS-CoV-2 spike proteins. We demonstrated that paucimannose-type glycans can successfully be converted to mammalian-type complex structures. To use the platform for vaccination studies further work directed towards the purification of the glycoengineered target proteins is necessary. In future, the platform will be used to also investigate the impact of glycosylation on therapeutic proteins. For this purpose further collaborations and funding are required. First results were published.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung